Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(11 sites) United States
Dana Farber Cancer Institute, Boston, Massachusetts University of Minnesota, Minneapolis, Minnesota Sarah Cannon Research Institute, Nashville, Tennessee Australia
Chris OBrien Lifehouse, Camperdown, New South Wales Calvary Mater Newcastle Hospital, Waratah, New South Wales Cabrini Hospital, Clayton, Victoria Peter MacCallum Cancer Centre, Melbourne, Victoria The Alfred Hospital, Melbourne, Victoria Switzerland
Kantonsspital Graubuenden, Chur Centre Hospitalier Universitaire Vaudois, Lausanne Kantonsspital Sankt Gallen, Sankt Gallen Key details Enrollment target
~60 participants
Primary completion
March 2028
Age range
18 Years and older
Last updated February 2026